Clinical Manifestations and Diagnosis of Bicuspid Aortic Valve in Adults
UpToDate Nov, Braverman, D.C., 2014
Stroke and Cancer - A Complicated Relationship
J Neurol Transl Neurosci 2:1039-1051, Dearborn, J.L.,et al, 2014
Preadmission Oral Anticoagulant Treatment and Clinical Outcome Among Patients Hospitalized with Acute Stroke and Atrial Fibrillation
Stroke 45:168-175, Johnsen, S.P.,et al, 2014
Nocardiosis of the Central Nervous System
Medicine 93:19-32, Anagnostou, T.,et al, 2014
Non-ST-Elevation Myocardial Infarction in Patients Undergoing Carotid Endarterectomy or Carotid Artery Stent Placement
Stroke 45:595-597, Khan, A.,et al, 2014
Effect of Citalopram on Agitation in Alzheimer Disease The CitAD Randomized Clinical Trial
JAMA 311:682-691, Porsteinsson, A.P.,et al, 2014
Symptomatic Peripheral Mycotic Aneurysms Due to Infective Endocarditis
Medicine 93:42-52, Gonzalez, I.,et al, 2014
Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials
Lancet 383:955-962,931, Ruff, C.T.,et al, 2014
Intracranial Atherosclerosis
Lancet 383:984-998, Qureshi, A. & Caplan, L.R., 2014
Factor Xa Inhibitors vs Warfarin for Preventing Stroke and Thromboembolism in Patients with Atrial Fibrillation
JAMA 311:1150-1151, Bruins Slot, K.M.H. & Berge, E., 2014
An Index to Identify Stroke-Related vs Incidental Patent Foramen Ovale in Cryptogenic Stroke
Neurol 81:619-625,619, Kent, D.M.,et al, 2013
Patent Foramen Ovale and Cryptogenic Stroke
Stroke 44:2676-2678, Furlan, A.J. and Jauss, M., 2013
Thrombolysis for Ischemic Stroke Associated with Infective Endocarditis
Stroke 44:2917-2919, Asaithambi, G.,et al, 2013
Faxtor Xa Inhibitors Versus Vitamin K Antagonists for Preventing Cerebral or Systemic Embolism in Patients with Atrial Fibrillation
Stroke 44:e165-e167, Bruins, K.M.H., & Berge, E., 2013
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013
Summary of Evidence-Based Guideline: Periprocedural Management of Antithrombic Medications in Patients with Ischemic Cerebrovascular Disease
Neurol 80:2065-2069, Armstrong, M.,et al, 2013
Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era
Am J Transplant 13:1512-1522, Evens, A.M.,et al, 2013
Complications and Outcome of Infective Endocarditis
UpToDate January, Spelman, D. & Sexton, D., 2012
Spinal Haemorrhage During Anticoagulant Regimen for Thromboprophylaxis: A Unique Form of Central Nervous System Haemorrhage
JNNP 83:746-752, Furlan, J.C.,et al, 2012
Critique of Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
Stroke 43:3147-3149, Thaler, D.E.,et al, 2012
Clinicopathologic Conference, Acute Ischemic Stroke due to Basilar Artery Embolism. Patent Foramen Ovale
NEJM 367:1450-1460, Case 31-2012, 2012
Management of Anticoagulation Before and After Elective Surgery
www.uptodate.com Dec. 2012, Lip, G. & Douketis, J., 2012
Critique of Apixaban Versus Warfarin in Patients with Atrial Fibrillation
Stroke 43:922-923, Nedeltchev,K, 2012
Risk of Stroke After Coronary Artery Bypass Grafting Effect of Age and Comorbidities
Stroke 43:38-43, Merie, C.,et al, 2012
Using Dabigatran in Patients with Stroke A Practical Guide for Clinicians
Stroke 43:271-279, Alberts, M.J.,et al, 2012
Left Atrial Catheter Ablation and Ischemic Stroke
Stroke 43:265-270, Haeusler, K.G.,et al, 2012
Patent Foramen Ovale Closure and Medical Treatments for Secondary Stroke Prevention
Stroke 43:422-431, Kitsios,G.D.,et al, 2012
Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
NEJM 366:991-999,1048, Furlan,A.J.,et al, 2012
Asymmetric Pattern of Cerebrovascular Lesions in Patients after Left Ventricular Assist Device Implantation
Stroke 43:872-874, Kato,T.S.,et al, 2012
Infective Endocarditis at Autopsy
Medicine 91:152-164, Fernandez Guerrero,M.L.,et al, 2012
Secondary Prevention after Ischemic Stroke or Transient Ischemic Attack
NEJM 366:1914-1922;, Davis, S.M. & Donnan, G.A., 2012
Stroke Recurrence in Children with Congenital Heart Disease
Ann Neurol 72:103-111, Rodan, L.,et al, 2012
Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease
NEJM 367:625-635, Olesen, J.B.,et al, 2012
Apixaban versus Warfarin in Patients with Atrial Fibrillation
NEJM 365:981-992,1052, Granger, C.B.,et al, 2011
Dronedarone in High-Risk Permanent Atrial Fibrillation
NEJM 365:2268-2276,2321, Connoly, S.J.,et al, 2011
Catheter Ablation for Atrial Fibrillation
NEJM 365:2296-2304, Wazni, O.,et al, 2011
Improved Late Survival and Disability After Stroke With Therapeutic Anticoagulation for Atrial Fibrillation
Stroke 42:2503-2508, Hannon, N.,et al, 2011
Progressive Multifocal Leukoencephalopathy in Transplant Recipients
Ann Neurol 70:305-322, Mateen, F.J.,et al, 2011
Rivaroxaban versus Warfarin in Nonvavular Atrial Fibrillation
NEJM 365:883-891, 952, Patel, M.R.,et al, 2011
Apixaban in Atrial Fibrillation From Bleeding Cows to 21st Century Medicinal Chemistry
Stroke 42:2376-2378, Cucchiara, B.L.,et al, 2011
Patients with Severe Asymptomatic Carotid Artery Stenosis Do Not Have a Higher Risk of Stroke and Mortality After Coronary Artery Bypass Surgery
Stroke 42:2801-2805, Mahmoudi, M.,et al, 2011
Hereditary Hemorrhagic Telangiectasia (Osler-Weber-Rendu Syndrome)
UpToDate, Feb, Shovlin, C., 2011
Dabigatran Etexilate versus Warfarin in Management of Non-Valvular Atrial Fibrillation in UK Context: Quantitative Benefit-Harm and Economic Analyses
BMJ 343:d6333, Pink, J.,et al, 2011
A New Landscape for Stroke Prevention in Atrial Fibrillation
Stroke 42:3316-3322, Banerjee, A.,et al, 2011
Temporal Onset, Risk Factors, and Outcomes Associated With Stroke After Coronary Artery Bypass Grafting
JAMA 305:381-390, Tarakji,K.G.,et al, 2011
An unusual cause of stroke and hypoxia
BMJ 342:c7200, Bell, S.L. & Eveson, D.J., 2011
Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data
Pharmacol Ther 129:185-194, Terry, K.W.,et al, 2011
Are all IV thrombolysis exclusion criteria necessary? Being SMART about evidence-based medicine
Neurol 76:1780-1781, Tong, D., 2011
Cost Effectiveness of Warfarin Versus Aspirin in Patients Older Than 75 Years With Atrial Fibrillation
Stroke 42:1717-1721, Jowett, S.,et al, 2011